Lenvatinib for the treatment of radioiodine-refractory follicular and papillary thyroid cancer

Bibliography

• Cramer JD, Fu P, Harth KC, et al. Analysis of the rising incidence of thyroid cancer using the Surveillance, Epidemiology and End Results national cancer data registry. Surgery 2010;148(6):1147-52; discussion 1152-3
   PubMed Web of Science ®Google Scholar
• Pellegriti G, Frasca F, Regalbuto C, et al. Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors. J Cancer Epidemiol 2013;2013:965212
   PubMedGoogle Scholar
• Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 2006;295(18):2164-7
   PubMed Web of Science ®Google Scholar
• Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64(1):9-29
   PubMed Web of Science ®Google Scholar
• Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer 1998;83(12):2638-48
   PubMed Web of Science ®Google Scholar
• Nixon IJ, Whitcher MM, Palmer FL, et al. The impact of distant metastases at presentation on prognosis in patients with differentiated carcinoma of the thyroid gland. Thyroid 2012;22(9):884-9
   PubMed Web of Science ®Google Scholar
• Mihailovic J, Stefanovic L, Malesevic M. Differentiated thyroid carcinoma with distant metastases: probability of survival and its predicting factors. Cancer Biother Radiopharm 2007;22(2):250-5
   Google Scholar
• Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994;97(5):418-28
   PubMed Web of Science ®Google Scholar
• Ruegemer JJ, Hay ID, Bergstralh EJ, et al. Distant metastases in differentiated thyroid carcinoma: a multivariate analysis of prognostic variables. J Clin Endocrinol Metab 1988;67(3):501-8
   PubMed Web of Science ®Google Scholar
• Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009;19(11):1167-214
   PubMed Web of Science ®Google Scholar
• Pacini F, Schlumberger M, Dralle H, et al. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 2006;154(6):787-803
   PubMed Web of Science ®Google Scholar
• Jarzab B, Sporny S, Lange D, et al. [Diagnosis and treatment of thyroid cancer - Polish guidelines]. Endokrynol Pol 2010;61(5):518-68
   PubMed Web of Science ®Google Scholar
• Durante C, Haddy N, Baudin E, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 2006;91(8):2892-9
   PubMed Web of Science ®Google Scholar
• Sampson E, Brierley JD, Le LW, et al. Clinical management and outcome of papillary and follicular (differentiated) thyroid cancer presenting with distant metastasis at diagnosis. Cancer 2007;110(7):1451-6
   PubMed Web of Science ®Google Scholar
• Pacini F, Ito Y, Luster M, et al. Radioactive iodine-refractory differentiated thyroid cancer: unmet needs and future directions. Expert Rev Endocrinol Metab 2012;7:541-54
   PubMedGoogle Scholar
• Schlumberger M, Sherman SI. Approach to the patient with advanced differentiated thyroid cancer. Eur J Endocrinol 2012;166(1):5-11
   PubMed Web of Science ®Google Scholar
• Droz JP, Schlumberger M, Rougier P, et al. Chemotherapy in metastatic nonanaplastic thyroid cancer: experience at the Institut Gustave-Roussy. Tumori 1990;76(5):480-3
   PubMed Web of Science ®Google Scholar
• Matuszczyk A, Petersenn S, Bockisch A, et al. Chemotherapy with doxorubicin in progressive medullary and thyroid carcinoma of the follicular epithelium. Horm Metab Res 2008;40(3):210-13
   PubMed Web of Science ®Google Scholar
• Tuttle R, Ball D, Byrd D, et al. NCCN Clinical Practice Guidelines in Oncology. Thyroid carcinoma. NCCN Guidel.2012;Version 2
   Google Scholar
• Bible KC, Suman VJ, Molina JR, et al. Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncol 2010;11(10):962-72
   PubMed Web of Science ®Google Scholar
• Cohen EW, Rosen LS, Vokes EE, et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol 2008;26(29):4708-13
   PubMed Web of Science ®Google Scholar
• Leboulleux S, Bastholt L, Krause T, et al. Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial. Lancet Oncol 2012;13(9):897-905
   PubMed Web of Science ®Google Scholar
• Gupta-Abramson V, Troxel AB, Nellore A, et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 2008;26(29):4714-19
   PubMed Web of Science ®Google Scholar
• Kloos RT, Ringel MD, Knopp MV, et al. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 2009;27(10):1675-84
   PubMed Web of Science ®Google Scholar
• Brose MS, Nutting CM, Jarzab B, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 2014;384(9940):319-28
   PubMed Web of Science ®Google Scholar
• Matsui J, Funahashi Y, Uenaka T, et al. Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res 2008;14(17):5459-65
   PubMed Web of Science ®Google Scholar
• Okamoto K, Kodama K, Takase K, et al. Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor model. Cancer Lett 2013;340(1):97-103
   PubMed Web of Science ®Google Scholar
• Glen H, Mason S, Patel H, et al. E7080, a multi-targeted tyrosine kinase inhibitor suppresses tumor cell migration and invasion. BMC Cancer 2011;11:309
   PubMed Web of Science ®Google Scholar
• Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer 2005;12(2):245-62
   PubMed Web of Science ®Google Scholar
• Xing M. Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer 2013;13(3):184-99
   PubMed Web of Science ®Google Scholar
• Ishigami SI, Arii S, Furutani M, et al. Predictive value of vascular endothelial growth factor (VEGF) in metastasis and prognosis of human colorectal cancer. Br J Cancer 1998;78(10):1379-84
   PubMed Web of Science ®Google Scholar
• George DJ, Halabi S, Shepard TF, et al. Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin Cancer Res 2001;7(7):1932-6
   PubMed Web of Science ®Google Scholar
• Fontanini G, Vignati S, Boldrini L, et al. Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma. Clin Cancer Res 1997;3(6):861-5
   PubMed Web of Science ®Google Scholar
• de la Torre NG, Buley I, Wass JA, Turner HE. Angiogenesis and lymphangiogenesis in thyroid proliferative lesions: relationship to type and tumour behaviour. Endocr Relat Cancer 2006;13(3):931-44
   PubMed Web of Science ®Google Scholar
• Bunone G, Vigneri P, Mariani L, et al. Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features. Am J Pathol 1999;155(6):1967-76
   PubMed Web of Science ®Google Scholar
• Klein M, Vignaud JM, Hennequin V, et al. Increased expression of the vascular endothelial growth factor is a pejorative prognosis marker in papillary thyroid carcinoma. J Clin Endocrinol Metab 2001;86(2):656-8
   PubMed Web of Science ®Google Scholar
• Sherman SI. Tyrosine kinase inhibitors and the thyroid. Best Pract Res Clin Endocrinol Metab 2009;23(6):713-22
   PubMed Web of Science ®Google Scholar
• St Bernard R, Zheng L, Liu W, et al. Fibroblast growth factor receptors as molecular targets in thyroid carcinoma. Endocrinology 2005;146(3):1145-53
   PubMed Web of Science ®Google Scholar
• Boss DS, Glen H, Beijnen JH, et al. A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours. Br J Cancer 2012;106(10):1598-604
   PubMed Web of Science ®Google Scholar
• Yamada K, Yamamoto N, Yamada Y, et al. Phase I dose-escalation study and biomarker analysis of E7080 in patients with advanced solid tumors. Clin Cancer Res 2011;17(8):2528-37
   PubMed Web of Science ®Google Scholar
• Shumaker R, Aluri J, Fan J, et al. Evaluation of the effects of formulation and food on the pharmacokinetics of lenvatinib (E7080) in healthy volunteers. Int J Clin Pharmacol Ther 2014;52(4):284-91
   PubMed Web of Science ®Google Scholar
• Sherman S, Jarzab B, Cabanillas M, et al. A phase II trial of the multitargeted kinase inhibitor E7080 in advanced radioiodine (RAI)-refractory differentiated thyroid cancer (DTC). J Clin Oncol 2011;29(Suppl):5503
   Web of Science ®Google Scholar
• Stjepanovic N, Capdevila J. Multikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinib. Biologics 2014;8:129-39
   PubMedGoogle Scholar
• Ball D, Sherman S, Jarzab B, et al. Lenvatinib treatment of advanced RAI-refractory differentiated thyroid cancer (DTC): cytokine and angiogenic factor (CAF) profiling in combination with tumor genetic analysis to identify markers associated with response. J Clin Oncol 2012;30(Suppl):5518
   Google Scholar
• Schlumberger M, Tahara M, Wirth L, et al. A phase 3, multicenter, double blind, placebo-controlled trial of lenvatinib (E7080) in patients 131I-refractory differentiated thyroid cancer (SELECT). J Clin Oncol 2014;32(Suppl):LBA6008
   Google Scholar
• Dadu R, Devine C, Hernandez M, et al. Role of salvage targeted therapy in differentiated thyroid cancer patients who failed first-line sorafenib. J Clin Endocrinol Metab 2014;99(6):2086-94
   PubMed Web of Science ®Google Scholar
• Schlumberger M, Jarzab B, Cabanillas M, et al. A phase II trial of multitargeted kinase inhibitor lenvatinib (E7080) in advanced medullary thyroid cancer (MTC). J Clin Oncol 2012;30(Suppl):5591
   Google Scholar
• Molina AM, Hutson TE, Larkin J, et al. A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC). Cancer Chemother Pharmacol 2014;73(1):181-9
   PubMed Web of Science ®Google Scholar
• Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 2007;96(12):1788-95
   PubMed Web of Science ®Google Scholar
• Eremina V, Sood M, Haigh J, et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 2003;111(5):707-16
   PubMed Web of Science ®Google Scholar
• Lambrechts D, Carmeliet P. VEGF at the neurovascular interface: therapeutic implications for motor neuron disease. Biochim Biophys Acta 2006;1762(11–12):1109-21
   PubMed Web of Science ®Google Scholar
• Qi W, Shen Z, Tang L, Yao Y. Congestive heart failure risk in cancer patients treated with VEGFR-TKIs: a systematic review and meta-analysis of 36 clinical trials. Br J Clin Pharmacol 2014. [Epub ahead of print]
   Google Scholar
• Qi WX, Sun YJ, Tang LN, et al. Risk of gastrointestinal perforation in cancer patients treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis. Crit Rev Oncol Hematol 2014;89(3):394-403
   PubMed Web of Science ®Google Scholar
• Zhang ZF, Wang T, Liu LH, Guo HQ. Risks of proteinuria associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a systematic review and meta-analysis. PLoS One 2014;9(3):e90135
   Web of Science ®Google Scholar
• QI WX, Min DL, Shen Z, et al. Risk of venous thromboembolic events associated with VEGFR-TKIs: a systematic review and meta-analysis. Int J Cancer 2013;132(12):2967-74
   PubMed Web of Science ®Google Scholar
• Izzedine H, Massard C, Spano JP, et al. VEGF signalling inhibition-induced proteinuria: mechanisms, significance and management. Eur J Cancer 2010;46(2):439-48
   PubMed Web of Science ®Google Scholar
• Keizer RJ, Gupta A, Mac Gillavry MR, et al. A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080. J Pharmacokinet Pharmacodyn 2010;37(4):347-63
   PubMed Web of Science ®Google Scholar
• Elisei R, Schlumberger MJ, Müller SP, et al. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol 2013;31(29):3639-46
   PubMed Web of Science ®Google Scholar
• Klein Hesselink EN, Klein Hesselink MS, de Bock GH, et al. Long-term cardiovascular mortality in patients with differentiated thyroid carcinoma: an observational study. J Clin Oncol 2013;31(32):4046-53
   PubMed Web of Science ®Google Scholar
• Shumaker RC, Zhou M, Ren M, et al. Effect of lenvatinib (E7080) on the QTc interval: results from a thorough QT study in healthy volunteers. Cancer Chemother Pharmacol 2014. [Epub ahead of print]
   Google Scholar
• Wells SA, Robinson BG, Gagel RF, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol 2012;30(2):134-41
   PubMed Web of Science ®Google Scholar
• Zang J, Wu S, Tang L, et al. Incidence and risk of QTc interval prolongation among cancer patients treated with vandetanib: a systematic review and meta-analysis. PLoS One 2012;7(2):e30353
   PubMed Web of Science ®Google Scholar
• Illouz F, Braun D, Briet C, et al. Thyroid effects of tyrosine kinase inhibitors. Eur J Endocrinol 2014;171(3):R91-9
   PubMed Web of Science ®Google Scholar
• Bowen JM. Mechanisms of TKI-induced diarrhea in cancer patients. Curr Opin Support Palliat Care 2013;7(2):162-7
   PubMed Web of Science ®Google Scholar